The call highlighted strong performance in certain products like BAQSIMI and strategic expansions in manufacturing. However, there were significant challenges including a decline in overall revenue, competition affecting multiple product lines, and pressure on margins, leading to a lower net income.

Company Guidance

During Amphastar Pharmaceuticals' second-quarter 2025 earnings call, the company reported net revenues of $174.4 million, a 4% decrease from the previous year's period, and a GAAP net income of $31 million or $0.64 per diluted share. The non-GAAP adjusted net income was $40.9 million or $0.85 per diluted share. BAQSIMI emerged as a significant contributor, with sales growing 21% year-over-year to $46.7 million due to increased unit volume and pricing. Primatene MIST maintained stable performance with $22.9 million in sales. However, glucagon injection and epinephrine sales fell 25% and 42%, respectively, due to increased competition. The company is expanding its California headquarters to quadruple domestic manufacturing capacity, enhancing operational resilience amid geopolitical challenges. Amphastar is optimistic about near-term FDA approval for its AMP-002 product and anticipates a GDUFA date for AMP-007 in the first half of 2026. The company is strategically focused on sustainable growth through pipeline advancement and increased R&D investment, with a 14% rise in R&D expenses year-over-year.

Strong BAQSIMI Performance

BAQSIMI sales grew to $46.7 million, up 21% year-over-year, driven by successful global commercialization and increased unit volume and higher average selling prices.

California Headquarters Expansion

Announced a significant expansion aimed at quadrupling manufacturing capacity, enhancing operational resilience and R&D pipeline advancement.

R&D and Regulatory Progress

R&D expense rose 14% year-over-year. Optimism for near-term approval of AMP-002 and progress in other regulatory programs, like AMP-007 and AMP-015, is on track.

Continued Success of Primatene MIST

Stable performance with sales holding steady at $22.9 million, reflecting consistent consumer demand.

Amphastar Pharmaceuticals (AMPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AMPH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	0.85 / -	0.96	―	―	―
Aug 07, 2025	2025 (Q2)	0.74 / 0.85	0.94	-9.57% (-0.09)
May 07, 2025	2025 (Q1)	0.69 / 0.74	1.04	-28.85% (-0.30)
Feb 27, 2025	2024 (Q4)	0.94 / 0.92	0.88	4.55% (+0.04)
Nov 06, 2024	2024 (Q3)	0.99 / 0.96	1.15	-16.52% (-0.19)
Aug 07, 2024	2024 (Q2)	0.77 / 0.94	0.65	44.62% (+0.29)
May 08, 2024	2024 (Q1)	0.77 / 1.04	0.62	67.74% (+0.42)
Feb 28, 2024	2023 (Q4)	0.91 / 0.88	0.73	20.55% (+0.15)
Nov 08, 2023	2023 (Q3)	0.69 / 1.15	0.38	202.63% (+0.77)
Aug 08, 2023	2023 (Q2)	0.56 / 0.65	0.39	66.67% (+0.26)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AMPH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$21.62	$23.81	+10.13%
May 07, 2025	$24.43	$24.65	+0.90%
Feb 27, 2025	$31.49	$28.43	-9.72%
Nov 06, 2024	$53.40	$46.09	-13.69%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Amphastar Pharmaceuticals (AMPH) report earnings?

Amphastar Pharmaceuticals (AMPH) is schdueled to report earning on Nov 10, 2025, After Close (Confirmed).

What is Amphastar Pharmaceuticals (AMPH) earnings time?

Amphastar Pharmaceuticals (AMPH) earnings time is at Nov 10, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AMPH EPS forecast?

AMPH EPS forecast for the fiscal quarter 2025 (Q3) is 0.85.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing